

Zatral[®]

Alfuzosin hydrochloride extended release tablet

DESCRIPTION

Zatral[®] contains alfuzosin hydrochloride, an orally active quinazoline derivative. It is a selective, peripherally acting antagonist of postsynaptic α_1 -adrenoceptors located in the prostate, bladder base and prostatic urethra. It is used for the functional symptoms of benign prostatic hyperplasia (BPH).

INDICATIONS

Zatral[®] is used for the treatment of functional symptoms of benign prostatic hyperplasia (BPH). It can also be used as a short-term treatment of acute urinary retention (AUR) related to BPH for patients older than 65 years in association with catheterisation.

DOSAGE AND ADMINISTRATIONS

BPH: One tablet once daily after meal.

AUR: One tablet once daily after meal should be taken from the first day of catheterisation. The treatment should be continued for 3-4 days (2-3 days during catheterisation and 1 day after its removal).

CONTRAINDICATIONS

Hypersensitivity to alfuzosin, history of orthostatic hypotension, incombination with other α -blockers and hepatic insufficiency.

SIDE-EFFECTS

Dizziness, headache, vertigo, malaise, tachycardia, palpitations, nausea, abdominal pain, rash, diarrhoea, asthenia, postural hypotension, syncope, dry mouth.

OVERDOSE

In case of over dosage, the patient should be hospitalized, kept in the supine position and conventional treatment of hypotension should take place. Alfuzosin is not dialyzable because of its high degree of protein binding.

DRUG INTERACTIONS

Alfuzosin in combination with other α -blockers is contraindicated.

WARNINGS

The administration of general anesthetics to patients receiving alfuzosin could cause profound hypotension. It is recommended that the tablets be withdrawn 24 hours before surgery.

USE IN PREGNANCY AND LACTATION

Due to the type of indication this section is not applicable.

PHARMACEUTICAL PRECAUTIONS

Store in a cool, dry place, away from light. Keep out of reach of children.

PACKAGING

Zatral[®] ER tablet: Box containing 6 strips of 4 tablets each. Each extended release tablet contains alfuzosin hydrochloride BP 10 mg.

SK+F

Manufactured by

ESKAYEF BANGLADESH LTD.

GAZIPUR, BANGLADESH

® REGD. TRADEMARK